ES2493619T3 - Composiciones y métodos para provocar el crecimiento de neuritas - Google Patents
Composiciones y métodos para provocar el crecimiento de neuritas Download PDFInfo
- Publication number
- ES2493619T3 ES2493619T3 ES10710598.3T ES10710598T ES2493619T3 ES 2493619 T3 ES2493619 T3 ES 2493619T3 ES 10710598 T ES10710598 T ES 10710598T ES 2493619 T3 ES2493619 T3 ES 2493619T3
- Authority
- ES
- Spain
- Prior art keywords
- nogo
- ngr1
- cells
- phosphorylation
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 238000000034 method Methods 0.000 title claims abstract description 37
- 230000014511 neuron projection development Effects 0.000 title abstract description 77
- 108010010919 Casein Kinase II Proteins 0.000 claims abstract description 191
- 102000052052 Casein Kinase II Human genes 0.000 claims abstract description 191
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 claims abstract description 173
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims abstract description 105
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims abstract description 105
- 102000005781 Nogo Receptor Human genes 0.000 claims abstract description 95
- 108020003872 Nogo receptor Proteins 0.000 claims abstract description 95
- 230000026731 phosphorylation Effects 0.000 claims abstract description 90
- 238000006366 phosphorylation reaction Methods 0.000 claims abstract description 90
- 210000002569 neuron Anatomy 0.000 claims abstract description 88
- 230000005764 inhibitory process Effects 0.000 claims abstract description 61
- 238000000338 in vitro Methods 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims description 76
- 241000282414 Homo sapiens Species 0.000 claims description 43
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 27
- 208000020431 spinal cord injury Diseases 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 230000023105 myelination Effects 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 230000007514 neuronal growth Effects 0.000 claims description 3
- 102000000343 Nogo Receptor 1 Human genes 0.000 claims 1
- 108010041199 Nogo Receptor 1 Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 165
- 108010077641 Nogo Proteins Proteins 0.000 description 131
- 102000010410 Nogo Proteins Human genes 0.000 description 131
- 230000011664 signaling Effects 0.000 description 78
- 210000002241 neurite Anatomy 0.000 description 57
- 108090000623 proteins and genes Proteins 0.000 description 55
- 102000004169 proteins and genes Human genes 0.000 description 52
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 51
- 229930002330 retinoic acid Natural products 0.000 description 51
- 229960001727 tretinoin Drugs 0.000 description 51
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 48
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 48
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 48
- 230000012010 growth Effects 0.000 description 43
- 230000000694 effects Effects 0.000 description 38
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 32
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 32
- 102000004196 processed proteins & peptides Human genes 0.000 description 31
- 230000008901 benefit Effects 0.000 description 30
- 229920001184 polypeptide Polymers 0.000 description 30
- 102000000473 Nogo Receptor 2 Human genes 0.000 description 28
- 108010041253 Nogo Receptor 2 Proteins 0.000 description 28
- 239000003112 inhibitor Substances 0.000 description 28
- 241000700159 Rattus Species 0.000 description 26
- 230000027455 binding Effects 0.000 description 26
- 239000012634 fragment Substances 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 25
- 230000008929 regeneration Effects 0.000 description 25
- 238000011069 regeneration method Methods 0.000 description 25
- 108010005298 Oligodendrocyte-Myelin Glycoprotein Proteins 0.000 description 23
- 102100026746 Oligodendrocyte-myelin glycoprotein Human genes 0.000 description 23
- 108091000080 Phosphotransferase Proteins 0.000 description 23
- 239000002609 medium Substances 0.000 description 23
- 102000020233 phosphotransferase Human genes 0.000 description 23
- 102000006386 Myelin Proteins Human genes 0.000 description 22
- 108010083674 Myelin Proteins Proteins 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 22
- 210000003169 central nervous system Anatomy 0.000 description 22
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 21
- 210000005012 myelin Anatomy 0.000 description 21
- 239000002953 phosphate buffered saline Substances 0.000 description 21
- 101100128415 Mus musculus Lilrb3 gene Proteins 0.000 description 20
- 101100236064 Rattus norvegicus Lilrb3l gene Proteins 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 18
- 229940095074 cyclic amp Drugs 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 15
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 230000006378 damage Effects 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 230000003834 intracellular effect Effects 0.000 description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 239000000710 homodimer Substances 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 210000003061 neural cell Anatomy 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 108010052285 Membrane Proteins Proteins 0.000 description 7
- 101710095853 Reticulon-4 receptor-like 1 Proteins 0.000 description 7
- 102100031540 Reticulon-4 receptor-like 1 Human genes 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000010166 immunofluorescence Methods 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 6
- 102000018697 Membrane Proteins Human genes 0.000 description 6
- 101710093481 Reticulon-4 receptor Proteins 0.000 description 6
- 102100029826 Reticulon-4 receptor Human genes 0.000 description 6
- 238000013528 artificial neural network Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 210000000944 nerve tissue Anatomy 0.000 description 6
- OLEKMOOQFWTQGD-UHFFFAOYSA-N 4-[[2-[[2-[[2-[2-[[2-[[2-[[2-[[2-[[2-[[2-[2-[[2-[[2-[[1-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[(2-acetamido-5-carbamimidamidopentanoyl)amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoylamino]-3-methylpentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-4-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]propanoylamino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-5-[[1-[[1-[[5-amino-1-[[6-amino-1-[[1-[[1-[[4-amino-1-[(1-amino-3-hydroxy-1-oxopropan-2-yl)amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound CCC(C)C(NC(=O)C(C)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(CO)NC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(C)NC(=O)C(CCCNC(N)=N)NC(=O)C(Cc1ccccc1)NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(CCCCN)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(C)=O)C(C)CC)C(C)C)C(C)CC)C(C)CC)C(C)C)C(=O)NC(CO)C(=O)NC(CCC(O)=O)C(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CCCCN)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CO)C(N)=O OLEKMOOQFWTQGD-UHFFFAOYSA-N 0.000 description 5
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 5
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 5
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 5
- 101000727477 Homo sapiens Reticulon-4 receptor Proteins 0.000 description 5
- 101001130247 Homo sapiens Reticulon-4 receptor-like 2 Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010029260 Neuroblastoma Diseases 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 102000048720 human RTN4R Human genes 0.000 description 5
- 102000053414 human RTN4RL2 Human genes 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102100040753 Casein kinase II subunit alpha' Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 101000892015 Homo sapiens Casein kinase II subunit alpha' Proteins 0.000 description 4
- 102000004866 Microtubule-associated protein 1B Human genes 0.000 description 4
- 108090001040 Microtubule-associated protein 1B Proteins 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 239000003966 growth inhibitor Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 229910001414 potassium ion Inorganic materials 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 4
- 239000012583 B-27 Supplement Substances 0.000 description 3
- 101001124058 Drosophila melanogaster Vesicle-fusing ATPase 1 Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- -1 NgR1 Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000001947 dentate gyrus Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000010185 immunofluorescence analysis Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000009689 neuronal regeneration Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 108010065251 protein kinase modulator Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000892026 Homo sapiens Casein kinase II subunit alpha Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 2
- 108010001441 Phosphopeptides Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 208000036815 beta tubulin Diseases 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 108091006004 biotinylated proteins Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 108010044493 collagen type XVII Proteins 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 108010036601 ectoprotein kinase Proteins 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 210000001353 entorhinal cortex Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000017511 neuron migration Effects 0.000 description 2
- 230000004031 neuronal differentiation Effects 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QUDAEJXIMBXKMG-UHFFFAOYSA-N 1-[2-[[2-[2-[[6-amino-2-[[2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]propanoylamino]-3-hydroxypropanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCCC(N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CO)C(=O)NCC(=O)N1CCCC1C(O)=O QUDAEJXIMBXKMG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- OMZYUVOATZSGJY-UHFFFAOYSA-N 4,5,6,7-tetrabromo-2h-benzotriazole Chemical compound BrC1=C(Br)C(Br)=C(Br)C2=NNN=C21 OMZYUVOATZSGJY-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101100080277 Caenorhabditis elegans ncr-1 gene Proteins 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229940122360 Casein kinase 2 inhibitor Drugs 0.000 description 1
- 229940122537 Casein kinase inhibitor Drugs 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 1
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 101710173787 Chondroitin sulfate proteoglycan 5 Proteins 0.000 description 1
- 102100028758 Chondroitin sulfate proteoglycan 5 Human genes 0.000 description 1
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 1
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 1
- 108010062306 Clostridium botulinum exoenzyme C3 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 206010061431 Glial scar Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 101000921226 Homo sapiens EH domain-containing protein 2 Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101000616778 Homo sapiens Myelin-associated glycoprotein Proteins 0.000 description 1
- 101001130250 Homo sapiens Reticulon-4 receptor-like 1 Proteins 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 101000994496 Homo sapiens cAMP-dependent protein kinase catalytic subunit alpha Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 101001130249 Mus musculus Reticulon-4 receptor-like 1 Proteins 0.000 description 1
- 101001130246 Mus musculus Reticulon-4 receptor-like 2 Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101150004005 Prkaca gene Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101150108294 Rtn4r gene Proteins 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 102100032791 cAMP-dependent protein kinase catalytic subunit alpha Human genes 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 102000046930 human EHD2 Human genes 0.000 description 1
- 102000054957 human LILRB1 Human genes 0.000 description 1
- 102000051756 human MAG Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000035771 neuroregeneration Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 229940043437 protein kinase A inhibitor Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000021930 regulation of neuron projection development Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- C12N9/1211—Thymidine kinase (2.7.1.21)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0903913 | 2009-03-06 | ||
| GBGB0903913.2A GB0903913D0 (en) | 2009-03-06 | 2009-03-06 | Compositions and methods |
| PCT/GB2010/000391 WO2010100428A2 (en) | 2009-03-06 | 2010-03-05 | Compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2493619T3 true ES2493619T3 (es) | 2014-09-12 |
Family
ID=40600640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10710598.3T Active ES2493619T3 (es) | 2009-03-06 | 2010-03-05 | Composiciones y métodos para provocar el crecimiento de neuritas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9089565B2 (OSRAM) |
| EP (1) | EP2403515B1 (OSRAM) |
| JP (1) | JP5670921B2 (OSRAM) |
| CN (1) | CN102341117B (OSRAM) |
| AU (1) | AU2010219463A1 (OSRAM) |
| CA (1) | CA2750911A1 (OSRAM) |
| DK (1) | DK2403515T3 (OSRAM) |
| ES (1) | ES2493619T3 (OSRAM) |
| GB (1) | GB0903913D0 (OSRAM) |
| WO (1) | WO2010100428A2 (OSRAM) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1066378A2 (en) | 1998-04-03 | 2001-01-10 | Curagen Corporation | Lyst protein complexes and lyst interacting proteins |
| US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| WO2003027228A2 (en) * | 2001-07-17 | 2003-04-03 | Incyte Genomics, Inc. | Receptors and membrane-associated proteins |
| JP2003093056A (ja) | 2001-09-26 | 2003-04-02 | Japan Science & Technology Corp | ｐ５３のＳｅｒ４６をリン酸化する酵素 |
| US20070025877A1 (en) | 2003-06-03 | 2007-02-01 | Hansen Christian M | User interface for portable medical diagnostic apparatus and method of using the same |
| GB0314943D0 (en) * | 2003-06-25 | 2003-07-30 | Proteome Sciences Plc | Screening methods |
| CN1849132A (zh) * | 2003-09-10 | 2006-10-18 | 伦敦大学国王学院 | 调节神经元生长的化合物以及它们的用途 |
| EP1695061A4 (en) * | 2003-12-16 | 2008-02-20 | Childrens Medical Center | METHOD OF TREATING NEUROLOGICAL DISORDERS |
| US20050214288A1 (en) * | 2004-03-26 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies against Nogo receptor |
| WO2006017673A2 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
| US7414637B2 (en) * | 2004-09-10 | 2008-08-19 | Telmap Ltd. | Placement of map labels |
| CA2684321A1 (en) | 2007-03-21 | 2008-09-25 | Effat Emamian | Compositions comprising pkac fragments and uses thereof for inhibiting akt1, p70s6k or abl activity |
-
2009
- 2009-03-06 GB GBGB0903913.2A patent/GB0903913D0/en not_active Ceased
-
2010
- 2010-03-05 DK DK10710598.3T patent/DK2403515T3/da active
- 2010-03-05 AU AU2010219463A patent/AU2010219463A1/en not_active Abandoned
- 2010-03-05 US US13/254,081 patent/US9089565B2/en not_active Expired - Fee Related
- 2010-03-05 EP EP10710598.3A patent/EP2403515B1/en not_active Not-in-force
- 2010-03-05 WO PCT/GB2010/000391 patent/WO2010100428A2/en not_active Ceased
- 2010-03-05 JP JP2011552505A patent/JP5670921B2/ja not_active Expired - Fee Related
- 2010-03-05 CA CA2750911A patent/CA2750911A1/en not_active Abandoned
- 2010-03-05 ES ES10710598.3T patent/ES2493619T3/es active Active
- 2010-03-05 CN CN201080009932.2A patent/CN102341117B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010100428A2 (en) | 2010-09-10 |
| DK2403515T3 (da) | 2014-08-11 |
| HK1166017A1 (en) | 2012-10-19 |
| GB0903913D0 (en) | 2009-04-22 |
| US9089565B2 (en) | 2015-07-28 |
| US20110318326A1 (en) | 2011-12-29 |
| CN102341117B (zh) | 2015-01-21 |
| JP5670921B2 (ja) | 2015-02-18 |
| CA2750911A1 (en) | 2010-09-10 |
| EP2403515B1 (en) | 2014-05-21 |
| CN102341117A (zh) | 2012-02-01 |
| EP2403515A2 (en) | 2012-01-11 |
| WO2010100428A3 (en) | 2010-10-21 |
| JP2012519676A (ja) | 2012-08-30 |
| AU2010219463A1 (en) | 2011-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Simon et al. | A caspase cascade regulating developmental axon degeneration | |
| ES2663226T3 (es) | Procedimientos y composiciones para tratar neuropatías | |
| Pernet et al. | Extracellular signal‐regulated kinase 1/2 mediates survival, but not axon regeneration, of adult injured central nervous system neurons in vivo | |
| Stichel et al. | Inhibition of collagen IV deposition promotes regeneration of injured CNS axons | |
| CN102316888A (zh) | 突触发生的调控 | |
| Cao et al. | Expression of nerve growth factor carried by pseudotyped lentivirus improves neuron survival and cognitive functional recovery of post‐ischemia in rats | |
| Bartel | Glial responses after chorda tympani nerve injury | |
| Mahbub Hasan et al. | Characterization of Xenopus egg membrane microdomains containing uroplakin Ib/III complex: roles of their molecular interactions for subcellular localization and signal transduction | |
| WO2011072484A1 (zh) | 脑损伤治疗的靶点和药物 | |
| Calderilla‐Barbosa et al. | Phosphorylation of dystrophin Dp71d by Ca2+/calmodulin‐dependent protein kinase II modulates the Dp71d nuclear localization in PC12 cells | |
| Chen et al. | Slit–Robo GTPase‐Activating Proteins are Differentially Expressed in Murine Dorsal Root Ganglia: Modulation by Peripheral Nerve Injury | |
| US9089565B2 (en) | Compositions and methods for causing neurite outgrowth | |
| Li et al. | Transsynaptic EphB/Ephrin-B signaling regulates growth of presynaptic boutons required for classical conditioning | |
| HK1166017B (en) | Compositions and methods for causing neurite outgrowth | |
| Yoo | Amphiregulin and growth differentiation factor 11 promote retinal ganglion cell survival in vivo through activation of Smad3 | |
| Tu | Deciphering Neuronal Signaling Within a Single Dendritic Spine in Long Term Potentiation | |
| Sayas et al. | Shaping the Brain by Neuronal Cytoskeleton: From Development to Disease and Regeneration | |
| Lu | Regulation of synaptic formation and maturation by synapse-associated E3 ubiquitin ligases at the neuromuscular junction | |
| Spencer | LPA receptors modulate gene expression during oligodendrocyte differentiation | |
| Shahsavani | Evaluating the role of Neuregulin-1β1 in neuroprotection after spinal cord injury | |
| Scott | The role of p75NTR in axonal regeneration and intraspinal plasticity following spinal deafferentation | |
| Cai | Investigating the Role of LIMK1 Signaling in PKA-dependent LTP in the Hippocampus | |
| Wang | PKC Mediates Inhibitory Effects of Myelin and Chondroitin Sulfate Proteoglycans on Axonal Regeneration | |
| Michelle et al. | The role of endothelial nitric oxide synthase and caveolin-1 in vascular permeability: Implications in tumor vascular permeability and tumor growth | |
| Attar | The Scaffolding Proteins IPCEF1/CNK3 and GRASP/TAMALIN Mediate Arf-to-Rac Crosstalk in Epithelial Cell Migration |